FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

AUROPHARMA Share Price Discussion

Aurobindo Pharma Ltd.
Sector: Pharmaceuticals and health care
... Read more
AUROPHARMA Share Price *
445 -4.15 (-0.92%)
* (quote may be delayed)

Find answers to all your questions on live AUROPHARMA message board: Is AUROPHARMA buy or sell? Should I buy AUROPHARMA shares? Why are AUROPHARMA shares falling? Should I invest in AUROPHARMA stock?


You can also check AUROPHARMA share price target recommended by brokerages.

AUROPHARMA Discussion Forum


Buy 440 PE @ 14. Target 20+
Like
reply
Reply
share
Share

AUROPHARMA FUTURE :- SELL 451 TGT 430/410 LOT SIZE 1000 PREMIUM SL 467
Like
reply
Reply
share
Share
JACKPOT FNO Call in AUROPHARMA
SELL AUROPHARMA FUTURE@456 SL 3 TARGET 456-440

Today's Low is 446.35
Like
reply
Reply
share
Share

SELL AUROPHARMA FUTURE@456 SL 3 TARGET 456-440
Like
reply
Reply (1)
share
Share
Latest replies

Today's low is 449.10
Rs 6900 PROFIT

Aurobindo pharma’s subsidiary, Auro Vaccines LLC, has entered into a definitive agreement to acquire certain business assets from Profectus BioSciences Inc., U.S., a clinical-stage vaccine development company.
Like
reply
Reply
share
Share
Aurobindo Pharma To Acquire Certain Assets Of Profectus BioSciences
The indicative time period for completion of acquisition is first half of 2020, the firm said.
BloombergQuint
Like
reply
Reply
share
Share

Aurobindo bought profectus Bioscience Inc undisclosed amount one more feather to add in portfolio
Like
reply
Reply
share
Share

BUY
DEC AUROPHARMA
@455_448
SL @430
TRG @500_530+
GO
500 CALL DEC
1
reply
Reply
share
Share

CS On Auobindo
Neutral, TP Rs 500
Unit IV Will Likely Require Re-inspection To Resolve Form 483 Observations
Approvals From Unit IV May Be Stuck For At Least 1 yr
Unit IV A/cs For 30% Of Pending ANDAs Having Higher Margins
Almost Half Of Pending ANDAs Could Be Stuck
Like
reply
Reply
share
Share

AUROPHARAM BTST CMP 453 SL 444
Like
reply
Reply (1)
share
Share
Latest replies
Pyramidstock @pyramidstock
Nov 28 3:01 PM

457+ Book profit

Buy AUROBINDO 460 call 2.75 sl below 1.70 tgt open
Like
reply
Reply
share
Share

SELL AUROPHARMA 453.50 & 455 SL 460 TG 444 SL VERY MUST BY ARUN
Like
reply
Reply
share
Share

Keep a eye on Aurobindo now
Like
reply
Reply
share
Share

Motilal Oswal target on AUROPHARMA
Date: 22-Nov-19 Broker: Motilal Oswal Price @ Call: 433.7 Target: 500 Recommendation: BUY
1
reply
Reply
share
Share

The company plans to achieve debt-free status in the next three years.
2
reply
Reply
share
Share
karan in AUROPHARMA
Buy auropharma at 435 SL 431.50 target 440 and ...

Auropharma made high 443. Call closed. Book 8 points
Like
reply
Reply
share
Share

buy auropharma cmp 438 sl 429 tgt 444-450-460
Like
reply
Reply (2)
share
Share
Latest replies
Pyramidstock @pyramidstock
Nov 25 4:43 PM

444+ 1st tgt done enjoy
Pyramidstock @pyramidstock
Nov 26 3:01 PM

449 enjoy keep trailing sl or book

Buy auropharma at 435 SL 431.50 target 440 and above
Like
reply
Reply
share
Share

CS On Auobindo
Neutral, TP Rs 500
Unit IV Will Likely Require Re-inspection To Resolve Form 483 Observations
Approvals From Unit IV May Be Stuck For At Least 1 yr
Unit IV A/cs For 30% Of Pending ANDAs Having Higher Margins
Almost Half Of Pending ANDAs Could Be Stuck
Like
reply
Reply
share
Share

USFDA finds several violations in Aurobindo sterile injections unit
FDA investigators have observed violations in sterilisation process to prevent microbial contamination and shortcomings in facility management procedures along with lapses in the design of the manufacturing plant...
Read more...
Like
reply
Reply
share
Share

USFDA inspected company's Unit IV at Hyderabad from November 4 to 13. At the end of the inspection, the company has been issued a 'Form 483' with 14 observations
Like
reply
Reply (3)
share
Share
Latest replies

Monday down trend or up trend

Negative news
Hyder @hydertasneem
Nov 24 3:21 AM

old news, already priced in
Calls Unlimited in AUROPHARMA
AURO ROCKING 443 TO 427 + 16000 CHAPO INDIA C...

MYSTERIOUS
AURO AGAIN TWICE
443 N BELOW NOW AT 425 + 17000
CHK HIGH N LOW
CHAPO INDIA CHAPO
Like
reply
Reply
share
Share

buy auropharma 460c3 at 5.7.5.8 target 6.7-7.5-8.2-9.05-10-10.9-11.65-13 stoploss 5
Like
reply
Reply
share
Share

Oops time #AuroPharma
Bulls must remain cautious else #Bears may attack any time soon
#Divergence
Like
reply
Reply
share
Share
Calls Unlimited in AUROPHARMA
AURO PHARMA ALL SET TO DO DOWN 460 NOT BROKEN W...

AURO ROCKING
443 TO 427 + 16000
CHAPO INDIA CHAPO
Like
reply
Reply
share
Share

AURO PHARMA
ALL SET TO DO DOWN
460 NOT BROKEN WE MAY SEE 380 DOWNSIDE ALSO
Like
reply
Reply
share
Share
Calls Unlimited in AUROPHARMA
446 ENTERING SOON ADVANCED LVL GIVEN TO PAID ME...

AURO 443 TO 435 + 8000
Like
reply
Reply
share
Share
karan in AUROPHARMA
Zeel...tata motors..lupin...cipla all are on a ...

Zeel 310
Cipla 280
Lupin 779
All rocked
Tata motor little disappointing.
Stay tuned for perfect levels.
Like
reply
Reply
share
Share

AUROPHARMA - 447027
View 20-11-2019 02:26Pm Aurobindo Pharma - LTP 444Rs
# Trading above Minor Support Level 435RS ...
Read more...
2
reply
Reply
share
Share

446 ENTERING SOON
ADVANCED LVL GIVEN TO PAID MEMBERS
Like
reply
Reply
share
Share

Zeel...tata motors..lupin...cipla all are on a bullish break out.
Like
reply
Reply
share
Share

440 to 449 --- rs. 9000 per lot on auropharma.
One solid call every day in NSE FUTURES.
YOU don't have to burn your eyes whole day.
Like
reply
Reply
share
Share

449.25....done. day traders book and exit.
Like
reply
Reply
share
Share

445.30 on the screen
Like
reply
Reply
share
Share

Buy auropharma at cmp 440 for 450/460/480. 2 days holding. Keep SL 4points
Like
reply
Reply
share
Share
Calls Unlimited in AUROPHARMA
auro 435 entering soon

SL HIT - 5000
Like
reply
Reply
share
Share

auro 435 entering soon
Like
reply
Reply
share
Share

Aurobindo Pharma-2QFY20 Result Update-13 November 2019.pdf
507 KB
Aurobindo Pharma
Earnings performance sustain despite compliance woes
Like
reply
Reply
share
Share

BUY AUROPHARAM CMP 430-429 SL 423 TGT 436-444-455
Like
reply
Reply (1)
share
Share
Latest replies
Pyramidstock @pyramidstock
Nov 20 9:38 PM

449.25 high enjoy..

CARRIED: BUY AUROPHARMA ABV 429
Like
reply
Reply
share
Share

429 sell on rise soon
Like
reply
Reply (4)
share
Share
Latest replies
puneet A K @puneetak
Nov 19 5:08 PM

Means what sir? Buy or sell. M new in market
Calls Unlimited @calls
Nov 19 5:52 PM

FULL DETAILS TO PAID MEMBERS ONLY..
puneet A K @puneetak
Nov 19 7:35 PM

Sorry not interest
Calls Unlimited @calls
Nov 19 7:45 PM

THNX
me too - not interested in FREE advice
Hansraj pandey in AUROPHARMA
BUY AURO PHARMA FUT 434 STOP LOSS 429 TARGET 4...

Sl hit book loss close position
Like
reply
Reply
share
Share

BUY AURO PHARMA FUT 434 STOP LOSS 429 TARGET 437/ 440+
Like
reply
Reply
share
Share

Auro pharma look bullish👍
Like
reply
Reply (1)
share
Share
Latest replies
Ahmed khan @Ahmedkahn
Nov 19 12:36 PM

426__437
Rakesh Kumar in AUROPHARMA
SELL 394 {TARGET:-387} S/L :- 396

Call not open
Like
reply
Reply
share
Share

buy auropahram cmp 403-402 Sl 394 tgt 410-418-427
Like
reply
Reply (2)
share
Share
Latest replies
Pyramidstock @pyramidstock
Nov 15 6:51 PM

415.85 kEEP TRALING SL SAFE PLAYER TOTALY BOOK AND RISKY ONE KEEP HOLD BUT WITH TRAILING SL
Pyramidstock @pyramidstock
Nov 18 6:11 PM

428THIS ALSO BECOME JACKPOT ENJOY

*BUY AUROPHARMA ABOVE 402 - SL 399 - TARGET 405 - 410*
Like
reply
Reply
share
Share

SELL 394 {TARGET:-387}
S/L :- 396
Like
reply
Reply
share
Share

AUROPHARMA - chart - 439488
(TMT) AURO PHARMA (395.30):- FORMING HARMONIC PATTERN WHITE SWAN, NOW REVERSAL ON CARD, ENTER AT 398-390 RANGE S/L 375 BELOW TGT 450-485+
Like
reply
Reply (6)
share
Share
Latest replies
TMT VIEW @tmtview
Nov 15 6:49 PM

AUROPHARMA NOW 410+
TMT VIEW @tmtview
Nov 18 5:53 PM

AUROPHARMA NOW 420+
TMT VIEW @tmtview
Nov 18 7:46 PM

AURO PHARMA NOW 425+
TMT VIEW @tmtview
Nov 20 5:10 PM

438 from 398.............40 pts up lot size 1000
TMT VIEW @tmtview
Nov 20 6:38 PM

AURO PHARMA NOW 445+........CATCH THE BIG MOVES BEFORE ITS COME NOT AFTER

Prabhudas Lilladher target on AUROPHARMA
Date: 14-Nov-19 Broker: Prabhudas Lilladher Price @ Call: 433.4 Target: 511 Recommendation: HOLD
Like
reply
Reply
share
Share
  • AUROPHARMA - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization46,051.74
    Enterprise Value50,495.97
    Price to Earnings18.01
    Price to Book Value4.06
    Return on Capital Employed0.17
    Return on Equity0.18
    Face Value1
    Dividend Yield0.01
  • AUROPHARMA Share Price - Technicals

    keyboard_arrow_down
    AUROPHARMA - 52 Week High₹838
    AUROPHARMA - 52 Week Low₹389.35
  • AUROPHARMA - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    22-Nov-19Motilal OswalBuy500
    14-Nov-19Prabhudas LilladherHold511
    10-Oct-19Reliance SecuritiesBuy575
    10-Oct-19Nirmal BangBuy761
    9-Oct-19Prabhudas LilladherHold511
    AUROPHARMA Brokerage Price Target
  • AUROPHARMA Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Dec 6449.15454.95442.25445.7
    Dec 5450.1456446.65449.15
    Dec 4441454.65440.45452.85
    Dec 3451452441.15445.55
    Dec 2452.7455447.5450.15
  • AUROPHARMA Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹437.98
    30 Day Moving Average₹448.78
    50 Day Moving Average₹481.56
    100 Day Moving Average₹535.33
    200 Day Moving Average₹626.54
  • AUROPHARMA - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue10,2709,607.050.07
    Operating Profit2,6702,373.950.12
    Profit Before Tax2,3432,178.570.08
    Net Income1,8131,706.760.06
  • AUROPHARMA - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds11,3519,9830.14
    Total Liabilities6,7906,1970.1
    Total Assets18,14116,1800.12
  • AUROPHARMA - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity9142,457.2-0.63
    Cash from Investing Activity-981-1,542.05-0.36
    Cash from Financing Activity440-1,328.99-1.33
    Net Cash Flow372-413.84-1.9
  • AUROPHARMA - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.110.13
    Return on Equity0.180.2
    Return on Capital Employed0.170.19
  • AUROPHARMA - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.27
    3 Year CAGR Growth in Operating Profit0.19
    3 Year CAGR Growth in EBIDTA0.19
    3 Year CAGR Growth in Net Income0.2
    3 Yr CAGR Growth - Diluted EPS-0.4
  • AUROPHARMA - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.89
    5 Year CAGR Growth in Operating Profit1.79
    5 Year CAGR Growth in EBIDTA1.79
    5 Year CAGR Growth in Net Income2.66
    3 Yr CAGR Growth - Diluted EPS0.82
  • AUROPHARMA - Recent News

    keyboard_arrow_down
    NewsBot
    Oct 18 1:38 PM
    Stocks in the news: Reliance Industries, Ambuja Cements, Aurobindo Pharma, KPR Mill
    Moneycontrol
    NewsBot
    Oct 14 10:58 PM
    Aurobindo Pharma breaks 2-day losing run; jumps 5%
    Moneycontrol
    NewsBot
    Oct 14 9:23 PM
    Aurobindo Q2 PAT seen up 6% YoY to Rs. 675.1 cr: Emkay
    Moneycontrol
    NewsBot
    Oct 12 5:08 PM
    Stock movers for the week: Bharti Airtel, Century Textiles, Bandhan Bank top the charts
    Moneycontrol
    NewsBot
    Oct 11 9:13 PM
    Aurobindo Pharma hits 5-year low after promoters create pledge earlier this week
    Moneycontrol
    NewsBot
    Oct 9 3:08 PM
    Aurobindo Pharma receives 7 observations from USFDA; share up 5%
    Moneycontrol
    NewsBot
    Oct 9 1:58 PM
    Stocks in news: DHFL, Aurobindo Pharma, Tata Motors, Titan, TCS, NMDC, Minda Industries
    Moneycontrol
    NewsBot
    Oct 8 11:43 PM
    Trade Setup for Wednesday: Top 15 things to know before Opening Bell
    Moneycontrol
    NewsBot
    Oct 7 11:03 PM
    Aurobindo Pharma gets 7 observations from USFDA for its Telangana unit
    Moneycontrol
    NewsBot
    Oct 7 8:08 PM
    Aurobindo Pharma tanks 19%, touches 5-year low
    Moneycontrol
  • AUROPHARMA - Related Communities

    keyboard_arrow_down
    MCX:RBDPMOLEIN
    MCX:PEPPER
    MCX:CASTORSEED
    MCX:CARDAMOM
    MCX:BRASSPHY
    Affle (India) Limited
    MCX:COTTON
    SPICEJET LTD Sector: Transport
    IRCTC Sector: Miscellaneous
    Share and discuss algorithms, strateg...
  • AUROPHARMA - More Information

    keyboard_arrow_down

    Aurobindo Pharma Ltd:
    Aurobindo Pharma Limited is propagating its business in researching, developing, manufacturing, and selling of several pharmaceutical products in India. Producing a significant variation in oral and injectable generic formulations, and active pharmaceutical ingredients and manufacturing peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries.
    Along with providing custom research and producing services to biotech and pharmaceutical community the company is reigning over antibiotic, anti-retroviral, cardiovascular, central nervous system, gastroenterological, anti-diabetic, and anti-allergy areas. Besides that, the company is manufacturing proteins, vitamins, minerals, and supplements, sports drinks etc.
    The company is exporting its products to almost 150 countries, including the U.S. and Europe along with serving multinational companies. The company is amongst the largest producers of Ampicillin and Cloxacillin in India. Aurobindo Pharma Limited was established in 1986 as a private limited company and headquartered in Hyderabad, Andhra Pradesh, India.
    About Company Information:
    Aurobindo Pharma was converted to a public limited firm in the year of 1992, after six years from its inception. The company built A CMIC chloride manufacturing unit at Pashamylaram near Hyderabad in the same year. The company started to issue bonus shares in a ratio of 1:1, 2:1 and 7:20 in ’92, ’93 and ’94 respectively. In 1993 the company built up another two plants at Bollaram and Kukatpally near Hyderabad. In 1994, the company increased the capacity at Pondicherry Unit from 204 TPA to 300 TPA along with increasing the installed capacity of its Bollaram unit from 78 TPA to 84 TPA. An amalgamation took place between the company and Chaitanya Organics Pvt. Ltd. in April 1994.
    Glaxo (India), a subsidiary of the U.K. based multinational Glaxo went for an alliance with Aurobindo Pharma in 1997, which increased the number of capsules and bulk drug up to 300 million and 840 tons respectively. In 1998, the company introduced Auronim Suspension in its pediatric segment. In FY 1999-2000, the company added a large section of Cephalosporins (Oral & Sterile) and anti-viral along with macrolides, quinolones, semi-synthetic penicillin, formulating for both the domestic and export market.
    During 2001-02 79% stake in Ranit Pharma Company were acquired by Aurobindo Pharma Ltd. A 50:50 joint venture firm of the company, namely Citadel Aurobindo Biotech Ltd, launched Aztreonam, a Monabactam Beta-lactam antibiotics as a debut in the Indian Pharma Market, TREONAM being the brand name, in 2003. In 2005-06, the company intervened in the markets of USA & Europe, with participation in the PEPFAR program, initiated by the US Govt. In March 2007, the FDA (U.S.) finally approved the company’s Didanosine Oral Suspension (Pediatric Powder) 10 mg/ml.
    Aurobindo Pharma acquired Moore and Carmiooro, the high profile OTC brands from TAD in 2008. AstraZeneca, a leading biopharmaceutical company in the international market, had gone for an agreement with Aurobindo Pharma, for supplying solid dosage and sterile products in 2010. A deal took place between Aurobindo Pharma and National Pharmaceutical Group Corporation, China, for launching the subsidiary Aurobindo (Datong) BioPharma Co Ltd, China (ADBPL).
    In April 2014, Aurobindo Pharma declared the completion of several business operations of Europe’s Actavis plc, an internationally recognized pharmaceutical company, manufacturing and supplying generic, brand and biosimilar products. On November 2016, a subsidiary of Aurobindo Pharma Ltd in France, namely Arrow Generiques SAS, signed an agreement to gain the right, title and interest in its products Calcium and Calcium Vitamin D3 in the French market, including the use of Teva Pharmaceutical Industries OROCAL trademark.
    On January 2017, Aurobindo Pharma declared about setting up a binding agreement by and through its solely owned subsidiary, Agile Pharma B.V., Netherlands, for acquiring Generis Farmaceutica SA, a pharmaceutical company of Portugal, against a lump sum of 135 million Euro totally including net working capital of 21.7 million Euro. On February 2017, four-cell culture derived biosimilar products from T.L. Biopharmaceutical AG were acquired by Aurobindo Pharma as declared by the company.
    How Aurobindo Pharma Ltd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Aurobindo Pharma Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Aurobindo Pharma Ltd, Competitors and Sector Peers:
    Aarey Drugs & Pharmaceuticals Ltd. AARDRU
    Aarti Drugs Ltd. AARTDR
    Aayush Food & Herbs Ltd. AAYFOO
    Abbott India Ltd. ABBIND
    ABL Bio-Technologies Ltd. ABLBIO
    Addlife Pharma Ltd. ADDPHA
    Bacil Pharma Ltd. BACPHA
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Brooks Laboratories Ltd. BROLAB
    Cipla Ltd. CIPLTD
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    Dujohn Laboratories Ltd. DUJLAB
    Earum Pharmaceuticals Ltd.
    Elder Health Care Ltd. ELDHEA
    Elder Pharmaceuticals Ltd. ELDPHA
    Elegant Pharmaceuticals Ltd. ELEPHA
    Gennex Laboratories Ltd. GENLAB
    Genomics Biotech Ltd. GENBIO
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    JK Pharmachem Ltd. JKPHAL
    Jubilant Life Sciences Ltd. JUBILO
    Jupiter Bioscience Ltd. JUPIBI
    Lupin Ltd. LUPLTD
    Lyka Labs Ltd. LYKLAB
    Novartis India Ltd. NOVAIN
    Ortin Laboratories Ltd. ORTLAB
    Piramal Enterprises Ltd. NICPIR
    Piramal Phytocare Ltd. PIRLIF
    Ranbaxy Laboratories Ltd. RANLAB
    Sanjivani paranteral Ltd. SANPAR
    Sanofi India Ltd. AVEPHA
    Sarvodaya Labs Ltd. SARLAB
    Sun Pharmaceutical Industries Ltd. SUN28
    TTK Healthcare Ltd. TTKHEA
    Venmax Drugs & Pharmaceuticals Ltd. YENDRU
    Venus Remedies Ltd. VENREM
    Zenith Healthcare Ltd. ZENHEA
    Zenlabs Ethica Ltd. SHRLAK
    Zenotech Laboratories Ltd. ZENLAB
    Zim Laboratories Ltd. ZIMLAB
    Zora Pharma Ltd.[Amalgamated] ZORPHA
    Zota Healthcare Ltd. ZOTHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.